Amplitude Ventures

Reverb Therapeutics focuses on developing innovative treatments for cancer and other diseases through advanced cytokine therapy. The company specializes in using bispecific antibodies to target and localize endogenous cytokines to immune cells within the tumor microenvironment. This approach aims to enhance targeted immune activation while minimizing the toxicity commonly associated with exogenously delivered cytokines. By leveraging the body's own cytokines, Reverb Therapeutics seeks to improve treatment outcomes for cancer patients, offering a promising alternative in the healthcare sector.

Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

Nomic is a bioengineering company focused on enhancing access to the human proteome, similar to the accessibility of the human genome. The company is developing the next-generation ELISA platform, known as nELISA, which is designed for high-throughput protein measurement. Nomic's solutions enable scientists to conduct protein profiling efficiently, allowing them to determine the scope and scale of their experiments. The platform features a cost-effective reagent system that integrates seamlessly with existing industry cytometers, facilitating high-throughput analysis and the creation of custom protein panels. By leveraging advanced technology, Nomic aims to empower researchers and nanotechnology developers to utilize DNA as a flexible and programmable linker, effectively addressing challenges such as cross-reactivity in protein measurements.

Radiant Biotherapeutics is an innovative biotechnology company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by creating multi-functional biologics designed to address challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging the principles of avidity and enhanced binding power, Radiant Biotherapeutics enables healthcare professionals to deliver potent therapies that have the potential to transform treatment outcomes for patients. The company's commitment to pioneering these advanced therapeutics positions it at the forefront of the biotherapeutics field, striving to unlock new avenues for patient care.

Ability Biologics is a biotechnology company focused on developing innovative immune-modulating biotherapeutics aimed at addressing significant unmet medical needs in patients suffering from cancer and autoimmune diseases. The company leverages a platform that employs advanced artificial intelligence to analyze a vast database of antigen-antibody interactions. This technology enables the creation of tailored and effective antibody therapeutics designed to provide healthcare professionals with potent treatment options for conditions that currently lack adequate solutions. Through its commitment to addressing these critical health challenges, Ability Biologics seeks to enhance patient outcomes and advance the field of immunotherapy.

Reverb Therapeutics focuses on developing innovative treatments for cancer and other diseases through advanced cytokine therapy. The company specializes in using bispecific antibodies to target and localize endogenous cytokines to immune cells within the tumor microenvironment. This approach aims to enhance targeted immune activation while minimizing the toxicity commonly associated with exogenously delivered cytokines. By leveraging the body's own cytokines, Reverb Therapeutics seeks to improve treatment outcomes for cancer patients, offering a promising alternative in the healthcare sector.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Radiant Biotherapeutics is an innovative biotechnology company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by creating multi-functional biologics designed to address challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging the principles of avidity and enhanced binding power, Radiant Biotherapeutics enables healthcare professionals to deliver potent therapies that have the potential to transform treatment outcomes for patients. The company's commitment to pioneering these advanced therapeutics positions it at the forefront of the biotherapeutics field, striving to unlock new avenues for patient care.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company employs a precision oncology platform that utilizes purpose-built vectors to deliver high-energy radio-isotopes directly to tumors and metastatic lesions. This innovative approach to targeted radiotherapy aims to improve treatment efficacy for patients with challenging cancer diagnoses. Abdera's work in this emerging field aligns with a significant market potential, as targeted alpha therapies are expected to play a major role in the future of nuclear medicine.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company employs a precision oncology platform that utilizes purpose-built vectors to deliver high-energy radio-isotopes directly to tumors and metastatic lesions. This innovative approach to targeted radiotherapy aims to improve treatment efficacy for patients with challenging cancer diagnoses. Abdera's work in this emerging field aligns with a significant market potential, as targeted alpha therapies are expected to play a major role in the future of nuclear medicine.

Congruence Therapeutics is a biotechnology company focused on developing pharmacological stabilizers for treating rare diseases. The company leverages computational and experimental drug discovery methods, along with structural bioinformatics, computational chemistry, and machine learning, to create an in silico platform. This platform enables the design of novel small molecules targeted at diseases caused by protein misfolding.

DrugBank is a developer of a comprehensive drug knowledge platform aimed at enhancing healthcare delivery and accelerating drug research. Their robust database provides extensive information on pharmaceuticals, including mechanisms of action, drug interactions, and allergy information, which empowers healthcare professionals to make informed decisions. The platform includes tools for drug search, interaction checking, and access to drug labels, facilitating precision medicine and clinical software applications. By integrating these resources into various software solutions via their API, DrugBank enables companies to scale their usage and expedite the development of novel drug candidates and predictive machine learning models. Additionally, DrugBank Online offers a free-to-use resource with limited datasets for academic and non-commercial research, contributing to its recognition in over 13,000 academic publications and its widespread use among millions of researchers and health professionals worldwide.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

Congruence Therapeutics is a biotechnology company focused on developing pharmacological stabilizers for treating rare diseases. The company leverages computational and experimental drug discovery methods, along with structural bioinformatics, computational chemistry, and machine learning, to create an in silico platform. This platform enables the design of novel small molecules targeted at diseases caused by protein misfolding.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target and modulate key protein-protein interactions. The company employs a comprehensive structure-guided drug discovery platform that includes target prediction and validation, hit identification from virtual and fragment libraries, and lead optimization. Gandeeva's preclinical oncology pipeline is designed to address challenging cancers through the creation of novel protein interaction modulators, specifically interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva Therapeutics aims to enhance treatment options and reduce the risks of late-stage clinical failures in oncology.

InVivo AI is a Montreal-based company founded in 2017 that specializes in leveraging artificial intelligence to enhance pharmaceutical research and development, with a particular focus on preclinical toxicology. The company has developed advanced AI methods for molecular representation, structure and ligand-based de novo design, and multiparameter optimization, enabling the creation of novel chemistry to address complex biological challenges.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapeutics for Long QT Syndrome and other arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, as well as atrial fibrillation and treatment-resistant cancers. Thryv Therapeutics specializes in creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to provide therapies that can significantly reduce the risk of sudden cardiac death and enhance the quality of life for patients affected by these serious conditions.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target various biological mechanisms in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug that aims to enhance drug tolerability and improve therapeutic outcomes. By releasing the active form of the drug specifically in the colon at the site of inflammation, Giiant's approach seeks to provide safer and more effective treatment options for patients suffering from IBD.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Founded in 2018 and headquartered in Toronto, Canada, the company specializes in induced pluripotent stem cell (iPSC) AlloCAR therapy products targeting non-Hodgkin lymphoma, leukemia, and multiple myeloma. Notch Therapeutics has created a proprietary T-cell production platform that allows for precise control of Notch signaling, a critical factor in T-cell development. This innovative approach addresses key limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. The technology empowers healthcare professionals to engineer stem cells tailored to the complex biology of various diseases, thereby enhancing the efficacy of cell therapies.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

Xap Therapeutics is a biotechnology start-up based in Cambridge, England, founded in 2017 by James Patterson, M.D., Ph.D. The company is focused on developing a synthetic biology-driven platform for cell therapeutics. This platform utilizes clustered regularly interspaced short palindromic repeats (CRISPR) technology to engineer induced pluripotent stem cells, creating a foundational "chassis" cell. These chassis cells can be functionalized into various cell therapies through genetically engineered constructs. Xap Therapeutics aims to enhance treatment options for serious diseases, including autoimmunity and cancer, by leveraging its innovative approach to cell therapy development.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

PHEMI Systems Corporation specializes in developing a comprehensive privacy, security, governance, and data management system optimized for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company focuses on the healthcare sector, offering the PHEMI Data Privacy Manager. This cloud-based platform addresses the critical need for healthcare organizations to secure, manage, and control access to sensitive information while ensuring compliance with privacy regulations. Built on a privacy-by-design architecture, PHEMI’s software facilitates data sharing and integrates seamlessly with numerous data sources, as well as popular data science and business analysis tools. The platform is designed to scale according to the organization's size and offers a flexible usage-based pricing model.

Shoebox develops validated iPad audiometers to help solve everyday problems faced by hearing health professionals and workplace safety managers. They offer solutions for occupational hearing testing. They offer validated online hearing screening, boothless diagnostic audiometers, and a comprehensive tele-audiology solution.

Imagia Cybernetics Inc. is a Montreal-based company that specializes in medical image analysis solutions aimed at cancer detection and management. The company focuses on early detection and quantification of cancer changes, which is crucial for improving patient outcomes. Imagia's Artificial Clinical Intelligence Platform delivers timely insights into primary tumors and metastasis, thereby personalizing the cancer care continuum for patients. Utilizing a unique approach called Deep Radiomics, which combines radiomics and deep learning, the platform analyzes routine clinical imaging data to identify robust biomarkers that can predict patient outcomes. By leveraging advancements in artificial intelligence and federated learning, Imagia enhances the capabilities of clinicians, enabling them to conduct predictive, diagnostic, and prescriptive analytics while maintaining data privacy.